Literature DB >> 33579788

Maintenance therapy with infliximab or vedolizumab in IBD is not associated with increased SARS-CoV-2 seroprevalence: UK experience in the 2020 pandemic.

Colleen Gc McGregor1, Alex Adams2, Ross Sadler3, Carolina V Arancibia-Cárcamo2, Rebecca Palmer2, Tim Ambrose2, Oliver Brain2, Alissa Walsh2, Paul Klenerman2, Simon Pl Travis2, Nicholas M Croft4,5, James O Lindsay4,5, Jack Satsangi2.   

Abstract

Entities:  

Keywords:  COVID-19; inflammatory bowel disease; infliximab; paediatric gastroenterology

Year:  2021        PMID： 33579788     DOI： 10.1136/gutjnl-2021-324116

Source DB:  PubMed          Journal:  Gut        ISSN： 0017-5749            Impact factor:   23.059


× No keyword cloud information.
  1 in total

1.  Turkish IBD Organization's Position Statement on Inflammatory Bowel Disease Management Recommendations During COVID-19 Pandemic.

Authors:  Murat Törüner; İsmail Hakkı Kalkan; Filiz Akyüz; Ahmet Tezel; Aykut Ferhat Çelik
Journal:  Turk J Gastroenterol       Date:  2021-06       Impact factor: 1.852
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.